Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Provided By PR Newswire
Last update: May 14, 2025
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25
Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash
Read more at prnewswire.comNASDAQ:PAVM (11/26/2025, 12:39:37 PM)
0.3546
+0.02 (+6.26%)
NASDAQ:LUCD (11/26/2025, 12:40:09 PM)
1.04
-0.05 (-4.59%)
Find more stocks in the Stock Screener
